At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 132 enrolled
Drug / intervention
Secukinumab +1 morebiological
Likely dose
Secukinumab 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exploratory Study on the Kinetics of Psoriasis Symptoms, Pruritus Intensity and Lesional Biomarkers in Patients With Moderate to Severe Plaque-type Psoriasis Treated With Subcutaneous Secukinumab (300 mg) During a 16 Week Open-label run-in Phase Followed by a 16 Week Randomized, Double-blind, Placebo-controlled Withdrawal Phase
In Brief
A Phase 3 clinical trial evaluating Secukinumab and Placebo for Psoriasis. Completed, enrolled 132 participants across 19 sites.
Detailed Summary
The study is designed to explore the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedFeb 2015
Primary CompletionJul 2016
TodayJul 2026
First PostedFeb 13, 2015
Enrollment StartJan 4, 2015
Primary CompletionJul 15, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.4 years ago
Interventions
Secukinumabbiological
150 mg secukinumab in 1 ml solution for subcutaneous injection (pre-filled syringe)
Placebobiological
Matching placebo in 1 ml solution for subcutaneous injection (pre-filled syringe)